Arius Features Preclinical Data on Antibody Candidates at Two Conferences

    TORONTO, Sept. 7 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that it will deliver poster presentations at two scientific
conferences reporting preclinical data for two of its anti-cancer antibody
drug candidates.
    At the 2007 Breast Cancer Symposium in San Francisco on September 7-8,
Arius will report recent results of its antibody candidate that targets CD44,
an antigen implicated as a cancer stem cell marker. The poster outlines recent
results for this antibody which demonstrate that it is a potent therapeutic in
breast cancer models both in vivo and in vitro. The poster also highlights the
prevalence of the epitope targeted by Arius' antibody in breast cancer
    The poster presentation is entitled "Development of a potent therapeutic
monoclonal antibody targeting CD44 in breast cancer" and will be presented at
General Poster Session D, 11:45-12:45 pm on Saturday, September 8th at the
San Francisco Marriott.
    At the XIth European Meeting on Complement in Human Disease held in
Cardiff, Wales on September 8-11, Arius will report results demonstrating that
its monoclonal antibody targeting CD59, a cell surface molecule involved in
regulating cell lysis mediated by the complement system, is a potent
therapeutic in various in vivo cancer models. Arius has demonstrated that its
antibody is highly potent at low doses and its efficacy in certain models
compares favorably to Taxotere.
    The poster presentation is entitled "AR36A36.11.1, a monoclonal antibody
targeting CD59, enhances complement activity and exhibits potent in vivo
efficacy in multiple human cancer models" and will be presented at Poster
Session 1: Inflammatory diseases, therapeutics and diagnostics, 4:00-6:00 pm
on Sunday, September 9th at Cardiff City Hall, Cathay's Park.

    About ARIUS

    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 400
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARIUS is listed on the TSX under the symbol "ARI". For further
information, visit

    Forward-Looking Statements

    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

For further information:

For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,,; James Smith, Investor
Relations, (416) 815-0700 ext. 229,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890